Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2011 May 15;21(10):2877-81. doi: 10.1016/j.bmcl.2011.03.088. Epub 2011 Mar 30.

A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor.

Author information

1
Department of Medicinal Chemistry, AstraZeneca R&D, Pepparedsleden 1, S-43183 Mölndal, Sweden. Peter.Bach@astrazeneca.com

Abstract

A novel series of P2Y(12) antagonists for development of drugs within the antiplatelet area is presented. The synthesis of the piperazinyl-pyridine urea derivatives and their structure-activity relationships (SAR) are described. Several compounds showed P2Y(12) antagonistic activities in the sub-micromolar range.

PMID:
21507636
DOI:
10.1016/j.bmcl.2011.03.088
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center